SCHEMBL1003366

SCHEMBL1003366

CC(C)c1ccc(NC(=O)c2cccc(Sc3ccccc3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.53
NPC1 O15118 7/20 0.53
RAB9A P51151 7/20 0.53
POLB P06746 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 2/20 0.53
HPGD P15428 1/20 0.53
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK1 P28482 1/20 0.45
RECQL P46063 1/20 0.45
MCL1 Q07820 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1000609 0.79 NPC1 (0.59) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL1001053 0.75 POLB (0.50) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL1003301 0.72 RAB9A (0.58) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL11469456 0.72 KDM4E (0.57) HPGDLMNAKDM4EMEN1KMT2A
SCHEMBL7612113 0.72 MAPT (0.44) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL10134912 0.71 POLB (0.51) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL2563194 0.71 NPC1 (0.68) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL15347911 0.70 POLB (1.00) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL22648796 0.70 RAB9A (0.52) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL26784590 0.69 RAB9A (0.62) SMN1; SMN2NPC1RAB9APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
CN-102015638-A Long-chain fatty acid elongase inhibitor containing arylsulfonyl derivative as active ingredient BANYU PHARMA CO LTD 2011-04-13 CN disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 SMN1; SMN2 965/4885NPC1 899/4885RAB9A 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.